Adagrasib and pembrolizumab combination therapy achieved a median PFS of 27.7 months in KRASG12C-mutated NSCLC patients with PD-L1 ≥50%. The combination therapy showed a 59.3% overall response rate, ...

Traditional Chinese medicine (TCM) pediatric tuina may be safe and effective as supplementary therapy in children with severe pneumonia.

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

Pneumonia, a largely preventable disease, caused more than two million deaths in 2021, according to the Global Burden of Disease report. Evidence-based guidance on its diagnosis and management is, ...

Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade Label Update ...